Ciltacabtagene autoleucel

CARVYKTI 3,2 × 10e6 - 1 × 10e8 CELULAS DISPERSION PARA PERFUSION

3.2 X 10⁶ -1.0 X 10⁸ CELULAS dispersion para perfusionSpainMarketedAuthorised 7 Jun 2022

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

CarvyktiEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Ciltacabtagene autoleucel

CARVYKTI 3,2 × 10e6 - 1 × 10e8 CELULAS DISPERSION PARA PERFUSION

3.2 X 10⁶ -1.0 X 10⁸ CELULAS dispersion para perfusionSpainMarketedAuthorised 7 Jun 2022

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

CarvyktiEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

CarvyktiUnited States · 0.5 to 1.0x10^6 chimeric antigen receptor (CAR)-positive viable T cells per kg of body weight, with a maximum dose of 1x10^8 CAR-positive viable T cells in one infusion · For Injection · Janssen Biotech, Inc.

Packs

Pack	Code	Status
CARVYKTI 3,2 × 10e6 - 1 × 10e8 CELULAS DISPERSION PARA PERFUSION, 30 o 70 ml	750584

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Ciltacabtagene autoleucel
Strength: 3.2 X 10⁶ -1.0 X 10⁸ CELULAS
Dosage form: dispersion para perfusion
Route: vía intravenosa
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 7 Jun 2022
Registration: 1221648001
Marketing authorisation holder: Janssen-Cilag International N.V
Procedure: EU centralised
Supply: Uso Hospitalario
EU number: EU/1/22/1648